0000899243-22-021638.txt : 20220609
0000899243-22-021638.hdr.sgml : 20220609
20220609170725
ACCESSION NUMBER: 0000899243-22-021638
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220607
FILED AS OF DATE: 20220609
DATE AS OF CHANGE: 20220609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOYCE MARTIN JOSEPH
CENTRAL INDEX KEY: 0001300858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 221006812
MAIL ADDRESS:
STREET 1: 1050 HINGHAM STREET
CITY: ROCKLAND
STATE: MA
ZIP: 02370
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-07
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001300858
JOYCE MARTIN JOSEPH
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
1
0
0
0
Stock Option (Right to Buy)
3.60
2022-06-07
4
A
0
53812
0.00
A
2032-06-06
Common Stock
53812
53812
D
Stock Option (Right to Buy)
3.60
2022-06-07
4
A
0
1624
0.00
A
2032-06-06
Common Stock
1624
1624
D
Stock Option (Right to Buy)
3.60
2022-06-07
4
A
0
6958
0.00
A
2032-06-06
Common Stock
6958
6958
D
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Martin Joyce
2022-06-09